Anzeige
Mehr »
Login
Samstag, 23.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Microsofts, Googles und Amazons nukleares Wettrennen macht diese Uranaktie zu einem Muss!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
496 Leser
Artikel bewerten:
(2)

TVM Capital Healthcare Announces Investment in Human Longevity, Inc. as Part of its Strategy of Supporting Disease Prevention and Healthy Aging

Finanznachrichten News

HLI is one of the most established, global longevity science companies and committed to accelerating living to 100+ years of a healthy, active, and mobile life

DUBAI, UAE and RIYADH, Saudi Arabia, Sept. 18, 2024 /PRNewswire/ -- TVM Capital Healthcare, an international healthcare expansion and growth capital firm, today announced a recent equity investment in San Francisco-based Human Longevity, Inc. (HLI), a global leader since 2013 in advancing precision medicine in the pursuit of healthy aging, often referred to as longevity medicine. The investment will support the company's growth within the U.S. market, as well as its expansion into the Kingdom of Saudi Arabia and Southeast Asia.

TVM Capital Healthcare Logo

Founded by Dr. J. Craig Venter, one of the pioneers of the human genome sequencing effort, HLI builds on his vision for a longer, healthier life and the democratization of genomics to revolutionize the way we evade "avoidable disease" and stay healthy longer. The company is recognized as a leader in the rapidly expanding industry of longevity medicine due to its deep expertise in genomics and other fields of precision medicine such as imaging, and its unmatched, longitudinal patient dataset built on decades of research in the field. The company has proprietary tools for the detection of gene-disease associations, including HLI's artificial intelligence health risk and recommendation platform, and provides its clients with pre-symptomatic diagnosis and customized treatments, preempting disease at a very early stage and maximizing health outcomes. In short, HLI is transforming healthcare from a reactive practice to one that is predictive, proactive, and preventative, which not only enhances the quality of lives of individuals but improves the efficiency and efficacy of the entire healthcare system.

TVM Capital Healthcare brings extensive global investment experience combined with operating experience in the Middle East and Southeast Asia and a track record of building innovative healthcare companies. Through this investment provided by the Saudi Arabia-focused TVM Healthcare Afiyah Fund LP, which closed earlier this year and is the largest growth capital fund of its kind in the region, the firm will support HLI in its expansion, initially with a special focus on market entry in the Kingdom. The country's Vision 2030 and Health Sector Transformation Program call for an evolution of "sick care" to true "health care," focusing on the most critical fields of oncology, neurology, metabolic syndrome, and diabetes, as well as cardiovascular and autoimmune disease. Saudi Arabia is highly receptive to healthcare business models such as HLI and has been increasingly active in longevity science with several government-backed initiatives, including the Saudi Human Genome Program and the Hevolution Foundation, a Riyadh-headquartered global non-profit organisation, investing in scientific projects and life science companies in the longevity field.

Dr. J. Craig Venter, Co-Founder and Chief Scientific Advisor of Human Longevity, Inc., commented: "Human Longevity, Inc. is a health firm where the goal is to stay ahead of aging and illness. We believe this platform will save millions of lives and significantly reduce healthcare costs in the future. TVM Capital Healthcare's investment enables us to strengthen our position globally as the most data-backed longevity practice, as well as establishes our foothold in markets, like Saudi Arabia and SEA, that see the potential of our approach in preventive medicine and the huge impact it will have on changing the cost of medicine."

Dr. Helmut M. Schuehsler, Chairman and CEO of TVM Capital Healthcare, remarked: "With our investment in HLI, we contribute to the transition towards the 'healthcare of the future' which is all about precision medicine, personalized care, and disease prevention, in short: true 'health care.' The potential long-term impact of longevity medicine in society is immense. We are excited to be part of the journey through this new investment which supports the growth of the company in the U.S., but also introduces HLI into the Kingdom of Saudi Arabia and Southeast Asia."

Dr. Ghida Harfouche, Partner at TVM Capital Healthcare, added: "HLI's cutting-edge science has enabled precision medicine for disease prevention and highly personalized interventions for their clients. We are pleased we can support the company in its global growth, and work with them on democratization of healthy longevity and preventative care."

TVM Capital Healthcare is recognized as the first international Healthcare fund manager investing in and operating healthcare companies in the Kingdom of Saudi Arabia. The firm is also active across the wider Middle East and Southeast Asia. In addition to backing healthcare growth companies in the U.S. and Europe to support their expansion plans into these regions, TVM Capital Healthcare also invests in leading local companies. With this two-pronged, highly catalytic strategy, TVM Capital Healthcare improves quality and affordable access to world-leading products, technologies, and services across its target markets.

ENDS

About TVM Capital Healthcare

TVM Capital Healthcare is a global healthcare private equity firm specializing in emerging markets. Based in Dubai and Singapore, with offices in Riyadh and Ho Chi Minh City, the firm invests expansion and growth capital in healthcare companies to improve local access to quality and affordable care, as well as local sources of medical products in the pharma, medical device, and diagnostics sectors. Investment and operating partners, as well as a strong group of regional and international senior advisors, have long-standing track records in healthcare investing and deep operating experience in the Middle East and Southeast Asia.

Medical quality is safeguarded by collaborations with leading international medical technology and clinical partners such as Mass General Hospital as well as international accreditation agencies such as Joint Commission International (JCI). TVM Capital Healthcare's investment and operating approach combines strong commercial value creation and financial returns with responsible and sustainable investment in alignment with the United Nations Sustainable Development Goals. Our proven strategy in the critical sector of healthcare also includes climate adaptation and resilience.www.tvmcapitalhealthcare.com

Contact:

Holly Radel
Radel@tvmcapitalhealthcare.com

Logo - https://mma.prnewswire.com/media/1446186/2740341/TVM_Capital_Healthcare_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/tvm-capital-healthcare-announces-investment-in-human-longevity-inc-as-part-of-its-strategy-of-supporting-disease-prevention-and-healthy-aging-302247907.html

© 2024 PR Newswire
Nach Nvidia: 5 KI-Revolutionäre aus der zweiten Reihe!
Künstliche Intelligenz hat spätestens nach dem Raketenstart von Chat GPT das Leben aller verändert. Doch der Superzyklus steht nach Meinungen von Experten erst am Anfang. Während Aktien wie Nvidia von der ersten Aufwärtsentwicklung stark profitieren konnten, versprechen aussichtsreiche Player aus der

zweiten Reihe noch enormes Aufwärtspotenzial.

Im kostenlosen, exklusiven Spezialreport präsentieren wir ihnen 5 innovative KI-Unternehmen, die bahnbrechende Entwicklungen in diesem Sektor prägen könnten.

Warum sollten Sie dabei sein?
Trotz der jüngsten Erfolge steht die Entwicklung der künstlichen Intelligenz noch am Beginn eines neuen Superzyklus. Experten gehen davon aus, dass der Sektor bis 2032 global auf 1,3 Billionen US-Dollar explodieren wird, wobei ein großer Teil auf Hardware und Infrastruktur entfallen wird.

Nutzen Sie die Chance!
Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche 5 KI-Aktien das größte Potenzial zur Vervielfachung besitzen. Dieser Report ist komplett kostenlos und zeigt Ihnen die aussichtsreichsten Investments im KI-Sektor.
Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.